Trial Profile
A Multicenter, 24-52-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Saredutant (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms MAGENTA
- Sponsors Sanofi
- 28 Jul 2011 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.